1stOncology™: Cancer Intelligence Service – Page 13306 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference

On August 29, 2019 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation to review upcoming potential milestones for the Company’s two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma and oral mucositis in head and neck cancer at the RHK Capital 2019 Disruptive Growth Conference on Wednesday, September 4, 2019 at 9:20 AM EDT (Press release, Soligenix, AUG 29, 2019, View Source [SID1234539134]). The event will take place at 599 Lexington Avenue, 22nd floor, New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

To access the Soligenix corporate presentation, please visit here.

About 2019 Disruptive Growth Conference

The 2019 (4th Annual) Disruptive Growth Conference organized by RHK Capital, and hosted by Reed Smith, offers an exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology.

For more information about the conference, please refer to the conference website.

Citius Pharmaceuticals, Inc. to Present at the RHK Capital 4th annual Disruptive Growth Conference hosted by Reed Smith.

On August 29, 2019 Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, reported that the Company will be presenting at the 4th annual Disruptive Growth Conference on Wednesday, September 4th at 3:40PM EST in Presentation Room A/B (Press release, Citius Pharmaceuticals, AUG 29, 2019, View Source [SID1234539133]). During the conference, Executive Chairman, Mr. Leonard Mazur will be giving the presentation as well as answering questions from investors.

Citius Pharmaceuticals, Inc. will also be available for one-on-one meetings. To arrange a meeting with the Company, please contact Mr. Andrew Scott: [email protected].

The 2018 Disruptive Growth Conference will offer the exclusive opportunity to discover growth companies with disruptive technologies and business models covering the following sectors: communications, consumer, energy/alternative energy, healthcare, industrial, life sciences, natural resources, and technology.

MEI Pharma to Present at the 2019 Wells Fargo Healthcare Conference

On August 29, 2019 MEI Pharma, Inc. (NASDAQ: MEIP), a late‐stage pharmaceutical company focused on advancing new therapies for cancer, reported that Daniel P. Gold, Ph.D., president and chief executive officer, will present at the 2019 Wells Fargo Global Healthcare Conference on Wednesday, September 4, 2019 at 11:25 a.m. ET (Press release, MEI Pharma, AUG 29, 2019, View Source [SID1234539132]). The conference will take place September 4‐5, in Boston, MA.

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of MEI Pharma’s website at View Source

An archived replay of the webcast will be available on MEI Pharma’s website for at least 30 days after the live event concludes.

Cellular Biomedicine Group to Present at Baird’s 2019 Global Healthcare Conference

On August 29, 2019 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that Derrick Li, Head of Strategy for the Company, will present at Baird’s 2019 Global Healthcare Conference to be held at the InterContinental New York Barclay in New York, NY on Thursday, September 5, 2019 at 9:40am ET (Press release, Cellular Biomedicine Group, AUG 29, 2019, View Source [SID1234539131]).

For more information about the conference, or to schedule a one-on-one meeting with CBMG management, please contact KCSA Strategic Communications at [email protected], your Baird representative directly, or send an email to [email protected].

CryoLife to Participate in Upcoming Investor Conferences

On August 29, 2019 CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, reported that it will participate in two upcoming investor conferences (Press release, CryoLife, AUG 29, 2019, View Source [SID1234539130]).

CryoLife’s management will be presenting at the Morgan Stanley 17th Annual Healthcare Conference in New York, New York on Wednesday, September 11, 2019 at 11:40 a.m. ET and will feature an overview of the company by Pat Mackin, Chairman, President and Chief Executive Officer. The live webcast can be accessed through CryoLife’s website, www.cryolife.com, on the Investor Relations page. An archived copy of the webcast will be available for 90 days on the same website.

CryoLife’s management will also be participating in investor meetings at the Lake Street 3rd Annual B.I.G. Conference in New York, New York on Thursday, September 12, 2019. Due to the format of this event no webcast will be available.